168 related articles for article (PubMed ID: 38430129)
1. Interleukin-2-induced skin inflammation.
Sommer C; Cohen JN; Dehmel S; Neuhaus V; Schaudien D; Braun A; Sewald K; Rosenblum MD
Eur J Immunol; 2024 Apr; 54(4):e2350580. PubMed ID: 38430129
[TBL] [Abstract][Full Text] [Related]
2. Stimulation of α7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro.
Wang DW; Zhou RB; Yao YM; Zhu XM; Yin YM; Zhao GJ; Dong N; Sheng ZY
J Pharmacol Exp Ther; 2010 Dec; 335(3):553-61. PubMed ID: 20843956
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-38 protects against sepsis by augmenting immunosuppressive activity of CD4
Ge Y; Huang M; Wu Y; Dong N; Yao YM
J Cell Mol Med; 2020 Jan; 24(2):2027-2039. PubMed ID: 31880383
[TBL] [Abstract][Full Text] [Related]
4. Tuning IL-2 signaling by ADP-ribosylation of CD25.
Teege S; Hann A; Miksiewicz M; MacMillan C; Rissiek B; Buck F; Menzel S; Nissen M; Bannas P; Haag F; Boyer O; Seman M; Adriouch S; Koch-Nolte F
Sci Rep; 2015 Mar; 5():8959. PubMed ID: 25753532
[TBL] [Abstract][Full Text] [Related]
5. IL-2/anti-IL-2 complexes ameliorate lupus nephritis by expansion of CD4
Yan JJ; Lee JG; Jang JY; Koo TY; Ahn C; Yang J
Kidney Int; 2017 Mar; 91(3):603-615. PubMed ID: 27914701
[TBL] [Abstract][Full Text] [Related]
6. Plasmodium falciparum-mediated induction of human CD25Foxp3 CD4 T cells is independent of direct TCR stimulation and requires IL-2, IL-10 and TGFbeta.
Scholzen A; Mittag D; Rogerson SJ; Cooke BM; Plebanski M
PLoS Pathog; 2009 Aug; 5(8):e1000543. PubMed ID: 19680449
[TBL] [Abstract][Full Text] [Related]
7. Expansion of CD25+ Innate Lymphoid Cells Reduces Atherosclerosis.
Engelbertsen D; Foks AC; Alberts-Grill N; Kuperwaser F; Chen T; Lederer JA; Jarolim P; Grabie N; Lichtman AH
Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2526-35. PubMed ID: 26494229
[TBL] [Abstract][Full Text] [Related]
8. CD25 shedding by human natural occurring CD4+CD25+ regulatory T cells does not inhibit the action of IL-2.
Pedersen AE; Lauritsen JP
Scand J Immunol; 2009 Jul; 70(1):40-3. PubMed ID: 19522766
[TBL] [Abstract][Full Text] [Related]
9. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
10. Low-Zone IL-2 Signaling: Fusion Proteins Containing Linked CD25 and IL-2 Domains Sustain Tolerogenic Vaccination
DeOca KB; Moorman CD; Garcia BL; Mannie MD
Front Immunol; 2020; 11():541619. PubMed ID: 33072087
[TBL] [Abstract][Full Text] [Related]
11. IL-33-responsive lineage- CD25+ CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs.
Bartemes KR; Iijima K; Kobayashi T; Kephart GM; McKenzie AN; Kita H
J Immunol; 2012 Feb; 188(3):1503-13. PubMed ID: 22198948
[TBL] [Abstract][Full Text] [Related]
12. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2.
Arenas-Ramirez N; Zou C; Popp S; Zingg D; Brannetti B; Wirth E; Calzascia T; Kovarik J; Sommer L; Zenke G; Woytschak J; Regnier CH; Katopodis A; Boyman O
Sci Transl Med; 2016 Nov; 8(367):367ra166. PubMed ID: 27903862
[TBL] [Abstract][Full Text] [Related]
13. Intranasal immunization with heat shock protein 60 induces CD4(+) CD25(+) GARP(+) and type 1 regulatory T cells and inhibits early atherosclerosis.
Zhong Y; Tang H; Wang X; Zeng Q; Liu Y; Zhao XI; Yu K; Shi H; Zhu R; Mao X
Clin Exp Immunol; 2016 Mar; 183(3):452-68. PubMed ID: 26452441
[TBL] [Abstract][Full Text] [Related]
14. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.
Rosenzwajg M; Churlaud G; Mallone R; Six A; Dérian N; Chaara W; Lorenzon R; Long SA; Buckner JH; Afonso G; Pham HP; Hartemann A; Yu A; Pugliese A; Malek TR; Klatzmann D
J Autoimmun; 2015 Apr; 58():48-58. PubMed ID: 25634360
[TBL] [Abstract][Full Text] [Related]
15. Characterization of protective human CD4CD25 FOXP3 regulatory T cells generated with IL-2, TGF-β and retinoic acid.
Lu L; Zhou X; Wang J; Zheng SG; Horwitz DA
PLoS One; 2010 Dec; 5(12):e15150. PubMed ID: 21179414
[TBL] [Abstract][Full Text] [Related]
16. Identification of tonsillar CD4
Sumitomo S; Nakachi S; Okamura T; Tsuchida Y; Kato R; Shoda H; Furukawa A; Kitahara N; Kondo K; Yamasoba T; Yamamoto K; Fujio K
J Autoimmun; 2017 Jan; 76():75-84. PubMed ID: 27653378
[TBL] [Abstract][Full Text] [Related]
17. Expression of IL-37 contributes to the immunosuppressive property of human CD4+CD25+ regulatory T cells.
Shuai X; Wei-min L; Tong YL; Dong N; Sheng ZY; Yao YM
Sci Rep; 2015 Sep; 5():14478. PubMed ID: 26411375
[TBL] [Abstract][Full Text] [Related]
18. Persistent IL-2 Receptor Signaling by IL-2/CD25 Fusion Protein Controls Diabetes in NOD Mice by Multiple Mechanisms.
Ward NC; Lui JB; Hernandez R; Yu L; Struthers M; Xie J; Santos Savio A; Dwyer CJ; Hsiung S; Yu A; Malek TR
Diabetes; 2020 Nov; 69(11):2400-2413. PubMed ID: 32843568
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells control CD4+CD25+ Treg cell suppressor function in vitro through juxtacrine delivery of IL-2.
Kulhankova K; Rouse T; Nasr ME; Field EH
PLoS One; 2012; 7(9):e43609. PubMed ID: 22984435
[TBL] [Abstract][Full Text] [Related]
20. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells.
Carter NA; Vasconcellos R; Rosser EC; Tulone C; Muñoz-Suano A; Kamanaka M; Ehrenstein MR; Flavell RA; Mauri C
J Immunol; 2011 May; 186(10):5569-79. PubMed ID: 21464089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
